Multiple sclerosis (MS), a chronic immune-mediated disease of the nervous system, is classified as a rare disease in China because of its low prevalence in that country. Traditionally, MS patients in China have been treated with disease-modifying therapies (DMTs) (IFN-β-1b [Bayer’s Betaferon], teriflunomide [Sanofi’s Aubagio], fingolimod [Novartis’s Gilenya], and siponimod [Novartis’s Mayzent]) and immunosuppressants (such as methotrexate, mitoxantrone, rituximab, azathioprine). In addition, the approval of ofatumumab (Novartis’s Kesimpta) and dimethyl fumarate (Biogen’s Tecfidera) in 2021 will boost the use of novel agents for the treatment of MS in China, thus increasing overall market sales. Despite the launch and availability of multiple DMTs in this market, pricing and reimbursement dynamics will continue to play a critical role in determining how the treatment paradigm will evolve over the next 10 years. Understanding these intersecting factors will be key to the success of current and future players in this market.
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 neurologists.
Diagnosed prevalence of MS (CIS, RR-MS, SP-MS, and PP-MS) in China, segmented by urban vs. rural; clinically relevant and market-relevant drug-treatable populations.
10-year, annualized, drug-level sales and patient share of key MS therapies through 2032, based on primary and secondary market research to formulate bottom-up assumptions.
Phase III/PR: 5 drugs; Phase II: 4 drugs; Phase I: 3 drugs.